TYRO3

TYRO3 Molekülinformation

Englischer Name	TYRO3 protein tyrosine kinase	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	Tyrosine-Protein Kinase RSE，BYK，Tyrosine-Protein Kinase Receptor TYRO3，Tyrosine-Protein Kinase BYK，Etk-2，Rek，DTK，SKY，TIF，Brt，RSE，Tyrosine-protein kinase DTK，Tyrosine-protein kinase SKY，TYRO3，Tyrosine-protein kinase TIF，TYRO3 Protein Tyrosine Kinase
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	TYRO3 protein tyrosine kinase
Target-Alias	Tyrosine-Protein Kinase RSE，BYK，Tyrosine-Protein Kinase Receptor TYRO3，Tyrosine-Protein Kinase BYK，Etk-2，Rek，DTK，SKY，TIF，Brt，RSE，Tyrosine-protein kinase DTK，Tyrosine-protein kinase SKY，TYRO3，Tyrosine-protein kinase TIF，TYRO3 Protein Tyrosine Kinase
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

TYRO3 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Fc Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TY3-H5251	Human	HEK293	Human TYRO3 / Dtk Protein, Fc Tag				In den Warenkorb legen

Gesamtmenge1

TYRO3 Molekülhintergrund

Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.

TYRO3 Molekülalias

TYRO3,BYK,DTK,RSE,SKY,TIF

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Insulin transdermal (Phosphagenics)	TPM-02	Phase 2 Clinical	Phosphagenics	Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Primary Ovarian Insufficiency	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Cabozantinib S-malate	XL-184; BMS-907351; RO7047650; RO-7047650	Approved	Exelixis Inc	Cometriq, Cabometyx	United States	Thyroid Neoplasms; Carcinoma, Neuroendocrine	Exelixis Inc	2012-11-29	Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin	Details